ARMP Armata Pharmaceuticals Inc
Price (delayed)
$2.26
Market cap
$81.77M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.85
Enterprise value
$196.03M
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is
Highlights
The equity has grown by 18% from the previous quarter
The company's debt has surged by 114% YoY but it fell by 13% QoQ
The company's net income has shrunk by 81% YoY but it rose by 16% QoQ
The company's quick ratio fell by 48% YoY and by 34% QoQ
ARMP's gross profit is down by 21% since the previous quarter and by 11% year-on-year
Key stats
What are the main financial stats of ARMP
Market
Valuations
Earnings
Shares outstanding
36.18M
Market cap
$81.77M
Enterprise value
$196.03M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
21.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
52.71
Revenue
$3.72M
EBIT
-$59.88M
EBITDA
-$58.73M
Free cash flow
-$46.07M
Per share
Balance sheet
Liquidity
EPS
-$1.85
Free cash flow per share
-$1.27
Book value per share
-$1.28
Revenue per share
$0.1
TBVPS
$2.9
Total assets
$108.31M
Total liabilities
$154.41M
Debt
$146.14M
Equity
-$46.1M
Working capital
-$92.28M
Debt to equity
-3.17
Current ratio
0.25
Quick ratio
0.27
Net debt/EBITDA
-1.95
Margins
Efficiency
Dividend
EBITDA margin
-1,579.3%
Gross margin
100%
Net margin
-1,802.7%
Operating margin
-1,130.9%
Return on assets
-61%
Return on equity
N/A
Return on invested capital
-41.4%
Return on capital employed
N/A
Return on sales
-1,610.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARMP stock price
How has the Armata Pharmaceuticals stock price performed over time
Intraday
3.67%
1 week
-5.83%
1 month
-0.44%
1 year
-16.3%
YTD
-30.25%
QTD
-17.82%
Financial performance
How have Armata Pharmaceuticals's revenue and profit performed over time
Revenue
$3.72M
Gross profit
$3.72M
Operating income
-$42.06M
Net income
-$67.04M
Gross margin
100%
Net margin
-1,802.7%
The company's net margin has shrunk by 103% YoY and by 6% QoQ
The company's net income has shrunk by 81% YoY but it rose by 16% QoQ
The company's operating margin fell by 34% QoQ and by 18% YoY
ARMP's gross profit is down by 21% since the previous quarter and by 11% year-on-year
Growth
What is Armata Pharmaceuticals's growth rate over time
Valuation
What is Armata Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
21.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
52.71
Armata Pharmaceuticals's EPS has shrunk by 80% YoY but it has increased by 16% QoQ
The equity has grown by 18% from the previous quarter
ARMP's price to sales (P/S) is 87% lower than its 5-year quarterly average of 172.1 and 21% lower than its last 4 quarters average of 27.9
The revenue is down by 21% since the previous quarter and by 11% year-on-year
Efficiency
How efficient is Armata Pharmaceuticals business performance
Armata Pharmaceuticals's return on sales has shrunk by 81% YoY
Armata Pharmaceuticals's ROA has plunged by 64% YoY but it has increased by 17% from the previous quarter
ARMP's return on invested capital is up by 20% since the previous quarter but it is down by 7% year-on-year
Dividends
What is ARMP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARMP.
Financial health
How did Armata Pharmaceuticals financials performed over time
ARMP's total assets is 30% lower than its total liabilities
The company's total liabilities has surged by 88% YoY but it fell by 13% QoQ
ARMP's current ratio has dropped by 52% year-on-year and by 34% since the previous quarter
ARMP's debt to equity has dropped by 189% year-on-year and by 7% since the previous quarter
The company's debt has surged by 114% YoY but it fell by 13% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.